PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

To:
VOSSIUS & PARTNER
Siebertstrasse 4
81675 München
GERMANY

EINGEGANGEN
Vossius & Partner
30. Juli 2001
Frist
bearb.:

	Date of mailing *(day/month/year)* 23/07/2001
Applicant's or agent's file reference D 2195 PCT	**FOR FURTHER ACTION** See paragraphs 1 and 4 below
International application No. PCT/EP 00/ 08761	International filing date *(day/month/year)* 07/09/2000
Applicant TRANSGENE S.A.	

1. [X] The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:
The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Fascimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. [ ] The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. [ ] **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

[ ] the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

[ ] no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90*bis*.1 and 90*bis*.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Sandra De Jong-van Dam

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international pbulication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the International application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped),whether

(i) the claim is unchanged;

(ii) the claim is cancelled;

(iii) the claim is new;

(iv) the claim replaces one or more claims as filed;

(v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."

2. [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."

3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]: "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."

4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
D 2195 PCT		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/EP 00/ 08761	07/09/2000	08/09/1999
Applicant		
TRANSGENE S.A.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the international Bureau.

This International Search Report consists of a total of 8 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

[ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

[X] contained in the international application in written form.

[X] filed together with the international application in computer readable form.

[ ] furnished subsequently to this Authority in written form.

[ ] furnished subsequently to this Authority in computer readble form.

[ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

[ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

[X] the text is approved as submitted by the applicant.

[ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**

[X] the text is approved as submitted by the applicant.

[ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. —

[ ] as suggested by the applicant.

[ ] because the applicant failed to suggest a figure.

[ ] because this figure better characterizes the invention.

[ ] None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/08761

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/47 C07K7/06 A61K38/17 A61K48/00
G01N33/50 G01N33/53 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 50527 A (BIOMIRA INC (CA); AGRAWAL B; KRANTZ M.J; REDDISH M.A; LONGENECKER B.M.) 12 November 1998 (1998-11-12)	1-11, 13-22, 26,27, 29,30, 35-37
	page 8, line 9,10; figure 12A	
Y	page 11, line 23,24 page 43; table III page 45, line 17; figure 9 page 47, line 5-18 claim 14	31,32
	--- -/--	

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
9 July 2001	23/07/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Macchia, G

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AGRAWAL B. ET AL.: "In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors" JOURNAL OF IMMUNOLOGY, vol. 157, no. 5, 1 September 1996 (1996-09-01), pages 2089-2095, XP002078857 ISSN: 0022-1767 page 2090	31,32

X	KAM J.L. ET AL.: "MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats" CANCER RESEARCH, vol. 58, 1 December 1998 (1998-12-01), pages 5577-5581, XP002171171 page 5578; table 1 page 5580; figure 3B	1-7,17, 18,20,37

X	AGRAWAL B. ET AL.: "The anti-MUC1 monoclonal atibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences" CANCER RESEARCH, vol. 58, 15 November 1998 (1998-11-15), pages 5151-5156, XP002171172	1-7,17, 18,20,37
A	page 5152; table 1 page 5155 -page 5156	19

X	APOSTOLOPOULOS V. ET AL.: "MUC1 peptide epitopes associated with five different H-2 class I molecules" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, October 1997 (1997-10), pages 2579-2587, XP001009768 page 2582 -page 2583; figures 2B,4A,5B,6A; table 1 page 2585; table 3 page 2587	1-7, 17-22, 26,27, 29,30, 35-37

X	APOSTOLOPOULOS V. ET AL.: "Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules" THE JOURNAL OF IMMUNOLOGY, vol. 161, 1998, pages 767-775, XP002171173 page 768, right-hand column -page 769; figure 1B	1-7,17, 18,20, 26,27, 29,30, 35-37

	-/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	APOSTOLOPOULOS V. ET AL.: "Induction of HLA-A2-restricted CTLs to the Mucin 1 human breast cancer antigen" THE JOURNAL OF IMMUNOLOGY, vol. 159, 1997, pages 5211-5218, XP002171238 page 5213, right-hand column, paragraph 2 page 5215; figure 3A ---	1-7, 17-22, 26,27, 29,30, 35-37
X	EP 0 369 816 A (UNIV MELBOURNE (AU); XING PEI-XIANG; MCKENZIE IAN FARQUHAR CAMPBELL) 23 May 1990 (1990-05-23) page 10, line 24-49, paragraph 2.4 page 15; table 2 page 4, column 37 -page 5, column 18 page 20; claims 22,24,25 ---	1-7, 17-22,37
X	XING PEI-XIANG ET AL.: "Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies" CANCER RESEARCH, vol. 50, no. 1, 1 January 1990 (1990-01-01), pages 89-96, XP001010017 page 90; table 1 page 93, right-hand column -page 94; figures 5,6 page 93 -page 94; figures 5,6 ---	1-7,17, 18,20,37
X	DOMÉNECH N. ET AL.: "Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen Mucin" THE JOURNAL OF IMMUNOLOGY, vol. 155, 1995, pages 4766-4774, XP002171174 page 4767; figure 1 page 4770; table I ---	1-7,17, 18,20, 26,27, 29,30,37
X	NISHIMORI I. ET AL.: "N-Acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts" CANCER RESEARCH, vol. 54, 15 July 1994 (1994-07-15), pages 3738-3744, XP002171175 page 3741 -page 3742; figures 3,5 ---	1-7,17, 20

-/--

6

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 06723 A (YEDA RES DEV CO LTD WEIZMANN INST SCI (IL) BIO-TECHNOLOGY GEN CORP (US) 10 February 2000 (2000-02-10) SEQ ID NO:43,44,47 page 4, line 35,36 page 40, line 9 -page 42, line 38; figures 18-22; example 4 page 54 -page 59; claims	1-4, 17-22, 26,27, 29,30, 35-37
P,X	CARMON L. ET AL.: "Novel breast-tumor-associated Muc1-derived peptides: characterization in Db-/- X beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain" INTERNATIONAL JOURNAL OF CANCER, vol. 85, no. 3, 1 February 2000 (2000-02-01), pages 391-397, XP001009767 page 393, left-hand column; table I	1-4, 17-22, 26,27, 29,30, 35-37
P,X	PIETERSZ G.A. ET AL.: "Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1" VACCINE, vol. 18, no. 19, April 2000 (2000-04), pages 2059-2071, XP004202504 ISSN: 0264-410X page 2065, right-hand column, paragraph 1 page 2066; table 3 page 2068, left-hand column, paragraph 1 page 2069; table 4	1-4,17, 18,20, 26,27, 29,30, 36,37
A	BROSSART P. ET AL.: "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies" BLOOD, vol. 93, no. 12, 15 June 1999 (1999-06-15), pages 4309-4317, XP002147432 ISSN: 0006-4971 page 4311; table 1	31,32

6

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-37 all partially

   A polypeptide consisting of or comprising at least one amino acid sequence of at most 20 consecutive amino acids defined in SEQ ID NO:1, said polypeptide binding at least one MHC-I glycoprotein, with the proviso that said polypeptide is different from SEQ ID NO:2.
   Said polypeptide wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:3 to SEQ ID NO:6, SEQ ID NO:65 and SEQ ID NO:66.
   Related polynucleotides, vectors, host cells, compositions, uses, vaccines, products, methods and kits.

2. Claims: 1-37 all partially

   As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:7 to SEQ ID NO:15.

3. Claims: 1-37 all partially

   As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:16 to SEQ ID NO:19.

4. Claims: 1-37 all partially

   As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:19 to SEQ ID NO:21.

5. Claims: 1-37 all partially

   As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:22 to SEQ ID NO:25.

6. Claims: 1-37 all partially

   As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:26 to SEQ ID NO:29.

7. Claims: 1-37 all partially

   As invention 1, wherein the amino acid sequence of the

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

polypeptide is selected from the group consisting of SEQ ID NO:30 to SEQ ID NO:33.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 33 and 34 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 35 (as far as an in vivo method is concerned) is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 23-25, 28 all totally; 26, 29, 30, 35-37 all partially

Present claim 23 relates to a T cell receptor, or a fragment thereof, present claims 24 and 25 relate to a T cell comprising said T cell receptor, present claim 28 relates to a method employing said T cell receptor or fragment thereof, present claim 36 relates in part to a pharmaceutical composition comprising said T cell.

None of these claims give a true technical characterization of said receptor. Moreover, no specific T cell receptors or T cells comprising said receptors are defined in the application.

Consequently, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed or supported (Articles 5 and 6 PCT).

No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Additionally, present claim 26 relates to a product defined by reference to a desirable characteristic or property, namely its capability to bind the T cell receptor of claim 23.

The claim covers all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products.
In fact, although the T cell receptor of claim 23 is not defined in present application, on pages 21-22 it is specified that the product to which claim 26 refers typically comprises (a) an MHC molecule, comprising a polypeptide (epitope) or analogue of the invention in its peptide groove, or (b) an analogue of (a) which is capable of inhibiting the binding of (a) to a T cell receptor of the invention. No other products having the above specified characteristic or property are defined in present application. Moreover, concerning the analogues of (a) which are capable of inhibiting the binding of (a) to the T cell receptor of the invention, present application recites on page 22 that " (b) is tipically a derivative of (a) and, thus, may be made by modifying (a) by any of the modifications mentioned herein ", said modifications being defined in pages 8-11 of present application. Again no specific analogues or derivatives are defined in present application.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claim which appear to be clear, supported and disclosed, namely those parts relating to (a) an MHC molecule, comprising a polypeptide (epitope) of the invention in its peptide groove, as defined on pages 21-22 of present application.

Moreover, present claim 29 relates in part to a cell comprising the product of claim 26, present claims 30 and 35 relate in part to a method employing said product or said cell, present claim 37 relates in part to a kit comprising said product.

Accordingly, the search has been carried out for those parts of these claims which appear to be clear, supported and disclosed, namely those parts relating to cells, methods and kits comprising (a) an MHC molecule, comprising a polypeptide (epitope) of the invention in its peptide groove.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 00/08761

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210

2. [X] Claims Nos.: 23-25, 28 all totally; 26, 29, 30, 35-37 all partially
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [X] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 00/08761

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9850527 A	12-11-1998	AU 727863 B	04-01-2001
		AU 7371298 A	27-11-1998
		EP 0986636 A	22-03-2000
EP 0369816 A	23-05-1990	CA 2003211 A	17-05-1990
		JP 2273195 A	07-11-1990
		ZA 8908777 A	28-12-1990
WO 0006723 A	10-02-2000	AU 5062999 A	21-02-2000
		EP 1100901 A	23-05-2001